Enhancing fibroblast activation protein (FAP)-targeted radionuclide therapy with albumin binding, and beyond
Sign Up to like & getrecommendations! Published in 2022 at "European Journal of Nuclear Medicine and Molecular Imaging"
DOI: 10.1007/s00259-022-05766-0
Abstract: Fibroblast activation protein (FAP) and its inhibitors (FAPI) have attracted tremendous attention worldwide over the last several years [1–4]. A number of radiolabeled FAPI have been designed, synthesized, and evaluated in preclinical models, and many… read more here.
Keywords: cancer; tumor; medicine; albumin binding ... See more keywords
Albumin binding function is a novel biomarker for early liver damage and disease progression in non-alcoholic fatty liver disease
Sign Up to like & getrecommendations! Published in 2020 at "Endocrine"
DOI: 10.1007/s12020-020-02319-z
Abstract: Purpose Indicators to assess early liver damage and disease progression in nonalcoholic fatty liver disease (NAFLD) remain unsatisfactory. Albumin binding function has been reported to be an early indicator of liver damage in hepatitis and… read more here.
Keywords: albumin binding; liver damage; disease; binding function ... See more keywords
Novel auristatin E‐based albumin‐binding prodrugs with superior anticancer efficacy in vivo compared to the parent compound
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Controlled Release"
DOI: 10.1016/j.jconrel.2019.01.010
Abstract: ABSTRACT Auristatins are a class of highly cytotoxic tubulin‐disrupting peptides, which have shown limited therapeutic effect as free agents in clinical trials. In our continuing effort to develop acid‐sensitive albumin‐binding anticancer drugs exploiting circulating serum… read more here.
Keywords: sulf07; binding prodrugs; albumin binding; auristatin ... See more keywords
Comparative Study on Covalent and Noncovalent Endogenous Albumin-Binding β-Glucuronidase-Activated SN38 Prodrugs for Antitumor Efficacy.
Sign Up to like & getrecommendations! Published in 2025 at "Journal of medicinal chemistry"
DOI: 10.1021/acs.jmedchem.4c03096
Abstract: Albumin-binding prodrugs have been explored to overcome the limitations of small-molecule anticancer chemotherapy agents, such as inadequate physiological and pharmaceutical compatibility, as well as rapid renal clearance. Herein, we investigated two endogenous albumin-binding prodrugs, M-g-SN38… read more here.
Keywords: antitumor efficacy; albumin binding; glucuronidase; endogenous albumin ... See more keywords
Modifying Antimicrobial Peptides with Albumin-Binding Molecules Enhances Membrane-Disrupting Efficacy by Modulating the Secondary Structure.
Sign Up to like & getrecommendations! Published in 2025 at "Journal of medicinal chemistry"
DOI: 10.1021/acs.jmedchem.5c00407
Abstract: Antimicrobial peptides (AMPs) are powerful tools in combating drug-resistant bacteria. However, their clinical application is hindered by poor pharmacokinetics and suboptimal antimicrobial activity. This study proposes a strategy to enhance the antimicrobial activity and biosafety… read more here.
Keywords: binding molecules; modifying antimicrobial; efficacy; antimicrobial activity ... See more keywords
86Y-Labeled Albumin-Binding Fibroblast Activation Protein Inhibitor for Late-Time-Point Cancer Diagnosis.
Sign Up to like & getrecommendations! Published in 2022 at "Molecular pharmaceutics"
DOI: 10.1021/acs.molpharmaceut.2c00579
Abstract: Fibroblast activation protein inhibitor (FAPI) is a novel quinoline-based radiopharmaceutical that has theranostic potential, yet the limited tumor retention hinders late-time diagnosis and radionuclide treatment. This study synthesized four albumin-binding FAPIs (TE-FAPI-01 to 04) and… read more here.
Keywords: activation protein; fapi; albumin binding; fibroblast activation ... See more keywords
In Vitro and In Vivo Study of Novel PSMA-Targeted Radioligands: Enhancing Tumor Uptake and Therapeutic Efficacy through Zwitterionization and Albumin-Binding Strategies.
Sign Up to like & getrecommendations! Published in 2025 at "Molecular pharmaceutics"
DOI: 10.1021/acs.molpharmaceut.5c00214
Abstract: Prostate-specific membrane antigen (PSMA) targeted radioligand therapy (TRT) for metastatic castration-resistant prostate cancer has demonstrated significant potential. This study aimed to develop an optimal radiotherapeutic agent suitable for high-level PSMA expression by optimizing the ligand… read more here.
Keywords: tumor uptake; psma targeted; albumin binding; psma ... See more keywords
Design and evaluation of novel thrombin-based GLP-1 analogs with peptidic albumin binding domain for the controlled release of GLP-1
Sign Up to like & getrecommendations! Published in 2020 at "RSC Advances"
DOI: 10.1039/d0ra00104j
Abstract: Currently, the curative effects of polypeptide drugs are often restricted due to the short in vivo duration of action. In this study, we fused a series of heptapeptide tags with different length fatty chains to… read more here.
Keywords: evaluation novel; albumin binding; glp; thrombin based ... See more keywords
Novel albumin-binding photothermal agent ICG-IBA-RGD for targeted fluorescent imaging and photothermal therapy of cancer
Sign Up to like & getrecommendations! Published in 2021 at "RSC Advances"
DOI: 10.1039/d0ra09653a
Abstract: In this work, we present a novel photothermal agent ICG-IBA-RGD based on albumin-binding strategy for enhanced tumor targeting imaging and photothermal therapy. read more here.
Keywords: photothermal agent; agent icg; iba rgd; icg iba ... See more keywords
An albumin-binding Gd-HPDO3A contrast agent for improved intravascular retention
Sign Up to like & getrecommendations! Published in 2021 at "Inorganic Chemistry Frontiers"
DOI: 10.1039/d1qi00128k
Abstract: A new Gd-HPDO3A derivative with improved MR contrast enhancing efficiency, demonstrated in a murine tumor model and in mouse models for stable and vulnerable atherosclerotic plaques, due to increased intravascular retention. read more here.
Keywords: intravascular retention; albumin binding; contrast; binding hpdo3a ... See more keywords
Extended plasma half-life of albumin-binding domain fused human IgA upon pH-dependent albumin engagement of human FcRn in vitro and in vivo
Sign Up to like & getrecommendations! Published in 2021 at "mAbs"
DOI: 10.1080/19420862.2021.1893888
Abstract: ABSTRACT Albumin has a serum half-life of 3 weeks in humans. This feature can be used to improve the pharmacokinetics of shorter-lived biologics. For instance, an albumin-binding domain (ABD) can be used to recruit albumin.… read more here.
Keywords: half life; life; albumin binding; human fcrn ... See more keywords